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TIGIT is a co-inhibitory molecule that limits T cell prolif-
eration and activation. TIGIT expression has been recently
shown to identify a subset of regulatory T cells (Treg) that
specifically suppresses Th1 and Th17 responses; however
its role in tumor immunity has not been examined. Here,
we determined whether TIGIT has a role in the suppres-
sion of anti-tumor immune responses. We found that
TIGIT is highly up-regulated on Treg and CD8+ tumor-
infiltrating lymphocytes (TILs) in multiple pre-clinical
cancer models. Importantly, TIGIT expression is strongly
associated with expression of other co-inhibitory mole-
cules; PD-1, Tim-3 and Lag-3 and with production of
IL-10 in Treg and CD8+ TILs. Moreover, TIGIT+ CD8+
TILs display an exhausted phenotype determined by
decreased production of IL-2 and TNF-a. To understand
whether TIGIT acts as a checkpoint in anti-tumor
response, we monitored growth of implanted B16 mela-
noma in TIGIT-/- mice and found that absence of TIGIT
significantly delayed tumor growth. As TIGIT is expressed
on both T cells (Treg and CD8+) and NK cells in cancer,
we addressed the role of TIGIT in these subsets in driving
immune suppression. Our data indicate that TIGIT may
play a dominant role in Treg in that deficiency of TIGIT
in Treg alone results in better control of tumor growth
and a heightened proliferative response in the draining
lymph nodes and spleens of tumor-bearing mice. Finally,
we show that a TIGIT blocking antibody can be used ther-
apeutically to decrease tumor growth and that blockade of
TIGIT synergizes with Tim-3 blockade to maximally
decrease tumor growth. Our study is the first report show-
ing that TIGIT acts as an immune checkpoint in cancer.
Importantly, our data indicate that TIGIT and Tim-3
synergize to suppress anti-tumor responses and targeting
these two molecules could provide a therapeutic effect on
tumor growth.
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